The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis

A S Avdeeva; M V Cherkasova; D A Kusevich; V V Rybakova; A S Artyuhov; Eh B Dashinimaev; N V Chichasova; E L Nasonov

doi:10.26442/00403660.2019.05.000230

Терапевтический архив (May 2019)

The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis

A S Avdeeva,
M V Cherkasova,
D A Kusevich,
V V Rybakova,
A S Artyuhov,
Eh B Dashinimaev,
N V Chichasova,
E L Nasonov

Affiliations

A S Avdeeva: V.A. Nasonova Scientific and Research Institute of Rheumatology
M V Cherkasova: V.A. Nasonova Scientific and Research Institute of Rheumatology
D A Kusevich: I.M. Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation (Sechenov University)
V V Rybakova: I.M. Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation (Sechenov University)
A S Artyuhov: Department of Regenerative Medicine; Institute of Developmental Biology, Russian Academy of Sciences, Laboratory of Cell Proliferation, Pirogov Russian National Research Medical University
Eh B Dashinimaev: Department of Regenerative Medicine; Institute of Developmental Biology, Russian Academy of Sciences, Laboratory of Cell Proliferation, Pirogov Russian National Research Medical University
N V Chichasova: V.A. Nasonova Scientific and Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation (Sechenov University)
E L Nasonov: V.A. Nasonova Scientific and Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation (Sechenov University)

DOI: https://doi.org/10.26442/00403660.2019.05.000230
Journal volume & issue: Vol. 91, no. 5
pp. 26 – 33

Abstract

Read online

Aim: to evaluate the role of laboratory biomarkers in monitoring effectiveness of rituximab (RTM) biosimilar therapy in a total dose of 1200 mg. Materials and methods. 20 patients (pts) with rheumatoid arthritis (RA) (18 woman, mean age 61.5(54-66.5) years, mean disease duration 39.5(20-84) months, mean DAS28 5.6(4.9-6.8)) received two intravenous RTM biosimilar infusions (600 mg №2) in combination with DMARDs and glucocorticoids. Laboratory biomarkers were assessed at baseline and weeks 12 and 24 after the first infusion of RTX. Results. RTM biosimilar induced decreases in DAS28, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) at week 12 and 24, p

Published in Терапевтический архив

ISSN: 0040-3660 (Print); 2309-5342 (Online)
Publisher: "Consilium Medicum" Publishing house
Country of publisher: Russian Federation
LCC subjects: Medicine
Website: http://ter-arkhiv.ru/en/

About the journal

Abstract

Keywords